- ASSOCIATE PROFESSOR Medicine
American Board of Internal Medicine
MD, University of Erlangen-Nurnberg
Fellowship, Tulane University
Internship, Tulane University
MD, Friedrich-Alexander University Erlangen-Nuremberg
MPH, Tulane University School of Public Health and Tropical Medicine
Residency, Tulane University
* Tulane University School of Medicine *
Residency, Infectious Diseases
* Tulane University School of Medicine *
- Dr. Ruhe did an Internal Medicine residency and an Infectious Diseases fellowship at Tulane University, New Orleans. His clinical and research interests are antibiotic resistance, antibiotic stewardship, and orthopedic infections.
Dr. Ruhe treats patients with HIV/AIDS and other infectious diseases including endocarditis, osteomyelitis, and infections caused by Staphylococcus aureus.
He also serves as the Director, Infectious Diseases, of the Antimicrobial Stewardship Program at Mount Sinai Beth Israel.
Infectious Diseases Society of America Trainee Award
Antimicrobial stewardship program at St. Luke’s Roosevelt Hospital Center and Beth Israel Medical Center-Petrie Division
Continuum Board of Trustees Award for Quality and Safety
ID Week Trainee Award (awarded to mentored Infectious Diseases fellow Krystina Woods, MD)
Infectious Diseases Society of America Trainee Award (awarded to mentored Infectious Diseases fellow Robert Goldstein, MD)
ID Week Trainee Award (awarded to mentored Infectious Diseases fellow Veenu Gill, MD)
2006 - 2007
George L. Ackerman Award, Outstanding Faculty in Internal Medicine
University of Arkansas for Medical Sciences
ResearchHis research interests include the epidemiology and therapy of multidrug-resistant organisms including MRSA and resistant gram-negatives.
Ruhe J, Holding K, Mushatt D. Infected total knee arthroplasty due to Actinomyces naeslundii. Scandinavian journal of infectious diseases 2001; 33(3).
Ruhe JJ, Hasbun R. Streptococcus pneumoniae bacteremia: duration of previous antibiotic use and association with penicillin resistance. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003 May; 36(9).
Ruhe JJ, Myers L, Mushatt D, Hasbun R. High-level penicillin-nonsusceptible Streptococcus pneumoniae bacteremia: identification of a low-risk subgroup. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004 Feb; 38(4).
Ruhe J, Menon A, Mushatt D, Dejace P, Hasbun R. Non- epidermidis coagulase-negative staphylococcal bacteremia: clinical predictors of true bacteremia. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2004 Jun; 23(6).
Ruhe JJ, Monson T, Bradsher RW, Menon A. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005 May; 40(10).
Ruhe JJ, Menon A. Clinical significance of isolated Staphylococcus aureus central venous catheter tip cultures. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2006 Sep; 12(9).
Ruhe JJ, Smith N, Bradsher RW, Menon A. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007 Mar; 44(6).
Ruhe JJ, Menon A. Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy 2007 Sep; 51(9).
Kielian T, Esen N, Liu S, Phulwani NK, Syed MM, Phillips N, Nishina K, Cheung AL, Schwartzman JD, Ruhe JJ. Minocycline modulates neuroinflammation independently of its antimicrobial activity in staphylococcus aureus-induced brain abscess. The American journal of pathology 2007 Oct; 171(4).
Ruhe JJ, Kreiswirth B, Perlman DC, Mildvan D, Koll B. Impact of results of methicillin-resistant Staphylococcus aureus surveillance culture of nasal specimens on subsequent antibiotic prescribing patterns. Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2010 Aug; 31(8).
Ruhe JJ, de Guzman L, Moss M, Riley W, Mildvan D, Perlman DC, Koll B. Methicillin-susceptible Staphylococcus aureus nasal colonization and the risk of subsequent methicillin-resistant Staphylococcus aureus infections among hospitalized patients. Diagnostic microbiology and infectious disease 2011 Oct; 71(2).
Ruhe J, Mildvan D. Does empirical therapy with a fluoroquinolone or the combination of a β-lactam plus a macrolide result in better outcomes for patients admitted to the general ward?. Infectious disease clinics of North America 2013 Mar; 27(1).
Nigo M, Cevallos CS, Woods K, Flores VM, Francis G, Perlman DC, Revuelta M, Mildvan D, Waldron M, Gomez T, Koshy S, Jodlowski T, Riley W, Ruhe JJ. Nested case-control study of the emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae. Antimicrobial agents and chemotherapy 2013 Nov; 57(11).
Goldstein RC, Husk G, Jodlowski T, Mildvan D, Perlman DC, Ruhe JJ. Fluoroquinolone- and ceftriaxone-based therapy of community-acquired pneumonia in hospitalized patients: the risk of subsequent isolation of multidrug-resistant organisms. American journal of infection control 2014 May; 42(5).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Ruhe did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
1st Ave & 16th St
New York, NY 10003